Repligen Corporation

NASDAQ:RGEN

Medical - Instruments & Supplies

Healthcare
$172.67 -2.74%

-$3.66 today

Market cap
$11.04B
Beta
1.08
P/E (TTM)
142.4
EPS (TTM)
$0.91
52W Low $100.99High $175.77

Volume 1.30M

Average 1.08M

RGEN EBITDA Margin

EBITDA as a percentage of revenue.

Repligen CorporationNASDAQ: RGEN

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 22.5%

EBITDA Margin was 22.5% in Q2 FY2026, down 4.0 pp from a year earlier. On a trailing-twelve-month basis it was 22.3%, up 5.6 pp year over year. Over 3 fiscal years it narrowed by 9.9 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 15 analysts of 30.1% for the fiscal year ending Dec 2026, up from 24.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
22.5%+5.9 pp QoQ
Last fiscal yearDec 2025
24.7%+12.1 pp YoY
LTMJun 2026
22.3%+5.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.0 pp+2.8 pp+6.8 pp
1 year+12.1 pp+5.4 pp-6.7 pp
3 years-9.9 pp+6.1 pp+16.0 pp
5 years+7.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
24.7%
Year-over-year change
+12.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How RGEN compares with its peers on the latest reported figures

  • RGEN's LTM Jun 2026 EBITDA Margin of 22.3% is the 5th highest of the 9 companies compared; the peer median is 21.8%.
  • Its year-over-year change of +5.6 pp is the 3rd highest of 9, against a peer median of -1.9 pp.
  • Over three fiscal years its change of -9.9 pp compares with a peer median of -1.7 pp.
RGEN Competitors Peer median
EBITDA Margin for RGEN and competitors
Company Period LTM level YoY 3-year change
QGENQiagen N.V.LTM Jun 202633.5% -1.6 pp-2.1 pp
AAgilent Technologies, Inc.LTM Jul 202627.6% +1.1 pp-1.4 pp
TECHBio-Techne CorporationLTM Sep 202626.8% +8.6 pp-11.9 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202623.7% -2.2 pp-0.9 pp
RGENRepligen CorporationLTM Jun 202622.3% +5.6 pp-9.9 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202619.9% -6.2 pp+208.5 pp
AVTRAvantor, Inc.LTM Jun 20261.9% -19.3 pp-18.1 pp
BLFSBioLife Solutions, Inc.LTM Mar 2026-7.5% -19.9 pp+166.6 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-26.6% +89.9 pp-148.5 pp
Peer median (excluding RGEN) 21.8%-1.9 pp-1.7 pp

Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue670.53M801.54M632.36M634.44M738.26M
Cost of Revenue279.28M345.83M353.92M359.79M390.63M
Gross Profit391.25M455.71M278.44M274.65M347.62M
Gross Margin58.3%56.9%44.0%43.3%47.1%
Research & Development34.27M43.94M42.72M43.2M54.18M
Selling, General & Admin183.87M215.83M218.58M263.37M290.51M
Operating Expenses224.01M231.04M230.74M309.76M288.05M
Depreciation & Amortization38.45M57.01M86.11M86.56M96.96M
EBITDA203.27M277.31M145.32M80.26M182.51M
EBITDA Margin30.3%34.6%23.0%12.7%24.7%
Operating Income167.25M224.67M47.7M(35.11M)59.58M
Operating Margin24.9%28.0%7.5%-5.5%8.1%
Interest Income176K6.98M0027.57M
Interest Expense12.71M2.98M10.03M22.57M23.17M
Other Income / Expenses(13.71M)(5.53M)9M8.08M2.81M
Income Before Tax153.54M219.14M56.71M(27.04M)62.38M
Pre-Tax Margin22.9%27.3%9.0%-4.3%8.5%
Income Tax Expense25.25M33.18M21.11M(1.52M)13.49M
Net Income128.29M185.96M35.6M(25.51M)48.89M
Net Margin19.1%23.2%5.6%-4.0%6.6%
EPS (Basic)2.333.350.64(0.46)0.87
EPS (Diluted)2.243.240.63(0.46)0.86
Weighted Avg Shares55.02M55.46M55.72M55.94M56.23M
Weighted Avg Shares (Diluted)57.26M57.46M56.38M55.94M56.56M

Repligen Corporation

NASDAQ:RGEN

Intrinsic Alpha fair value

Locked

Current Price

$172.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.